Refractory Malignant Neoplasm Recruiting Phase 1 Trials for Everolimus (DB01590)

IndicationStatusPhase
DBCOND0074899 (Refractory Malignant Neoplasm)Recruiting1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01582191Vandetanib and Everolimus in Treating Patients With Advanced or Metastatic CancerTreatment